Sector News

Shire R&D chief Andy Busch jumps ship to Ironwood spinout

April 11, 2019
Life sciences

Rare disease biotech Cyclerion has poached Shire’s ex-head of R&D, Andy Busch, Ph.D., as its new chief innovation officer, less than 18 months after he joined the company from his long stint at Bayer.

Busch joins after his former employer, rare disease specialist Shire, was recently bought out by Japanese pharma Takeda. He had signed up as the Big Biotech’s EVP and head of research and development, as well as its chief scientific officer, back in December 2017.

Before that, he had served a major 13-year stint at German pharma Bayer as its executive vice president, head of drug discovery, where he worked on its early stage development work. Also a Sanofi alumnus, Busch left Bayer after it reworked its R&D structure, combining its pharma R&D unit under one division and under one leader, namely Joerg Moeller, who had been its head of development within the pharma’s pharmaceuticals division.

It looks as if the merger with Takeda may have also created new structural changes.

He’ll report to Peter Hecht, Ironwood’s CEO and founder, who left to head up Cyclerion, which was spun out of his former company’s R&D department, and Mark Currie, Ph.D., president and chief scientific officer, who helped build the company’s platform.

With his new role, Busch will lead Cyclerion’s so-called “Innovation Center,” the company’s leadership model that “gathers research, development, customer insights and external innovation together in one team to identify, advance and optimize value-creating medicines,” according to a statement.

In essence, his job is to get the best out of Cyclerion’s current pipeline of five soluble guanylate cyclase (sGC) stimulator programs for orphan diseases.

These programs include olinciguat, currently in in phase 2 for sickle cell disease; praliciguat in phase 2 trials for heart failure with preserved ejection fraction (HFpEF) and for diabetic nephropathy; IW-6463, in phase 1 development for serious and orphan central nervous system diseases; and two late-stage discovery programs targeting serious liver and lung diseases, respectively.

By Ben Adams

Source: Fierce Biotech

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).